US Bancorp DE Acquires 26,467 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

US Bancorp DE raised its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 3,524.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,218 shares of the company’s stock after purchasing an additional 26,467 shares during the quarter. US Bancorp DE’s holdings in Caribou Biosciences were worth $43,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after purchasing an additional 124,782 shares during the last quarter. Barclays PLC lifted its position in shares of Caribou Biosciences by 122.4% during the third quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Caribou Biosciences by 19.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock worth $1,449,000 after purchasing an additional 118,325 shares during the last quarter. FMR LLC lifted its position in shares of Caribou Biosciences by 7.4% during the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after purchasing an additional 109,606 shares during the last quarter. Finally, Green Alpha Advisors LLC lifted its position in shares of Caribou Biosciences by 75.4% during the fourth quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock worth $288,000 after purchasing an additional 77,840 shares during the last quarter. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Price Performance

CRBU stock opened at $0.95 on Wednesday. The business has a 50-day moving average price of $1.33 and a 200 day moving average price of $1.76. The company has a market capitalization of $88.38 million, a P/E ratio of -0.58 and a beta of 2.34. Caribou Biosciences, Inc. has a 1-year low of $0.95 and a 1-year high of $5.77.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. The firm had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on CRBU shares. Bank of America decreased their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Citigroup decreased their price objective on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.